Advanced pediatric myelodysplastic syndromes: Can immunophenotypic characterization of blast cells be a diagnostic and prognostic tool?

Veltroni, Marinella; Sainati, Laura; Zecca, Marco; Fenu, Susanna; Tridello, Gloria; Testi, Anna Maria; Merlone, Alessandra Di Cesare; Buldini, Barbara; Leszl, Anna; Nigro, Luca Lo; Longoni, Daniela; Bernini, Gabriella; Basso, Giuseppe

doi:10.1002/pbc.21874

Cited by 28 publications

(23 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Figure S2), as previously published. 23,24 As expected, AA presented with a lower total progenitor frequency (assessed as CD34 pos or CD117 …”

Section: T Cells In Gata-2-deficient Patients Are Proportionally Incrsupporting

confidence: 76%

See 1 more Smart Citation

Loss of B cells and their precursors is the most constant feature of GATA-2 deficiency in childhood myelodysplastic syndrome

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Figure S2), as previously published. 23,24 As expected, AA presented with a lower total progenitor frequency (assessed as CD34 pos or CD117 …”

Section: T Cells In Gata-2-deficient Patients Are Proportionally Incrsupporting

confidence: 76%

“…23,24 The lowest proportion of B cells was present in GATA-2-deficient patients (Table 3 and Figure 1). The highest proportion of B cells was present in the AA group, which may be explained by a severe reduction in the myeloid compartment and relative lymphocytosis.…”

Section: B-cell Compartment Composition and Production Of B Cells Exhmentioning

confidence: 98%

Loss of B cells and their precursors is the most constant feature of GATA-2 deficiency in childhood myelodysplastic syndrome

et al. 2016

View full text Add to dashboard Cite

show abstract

“…In advanced pediatric MDS, CD7 expression on myeloid blast cells was described to correlate with dismal survival. 21 We recently showed that, in RCC, a simple and reproducible flow cytometric scoring system, described by Ogata and others as a diagnostic tool in adult low-grade MDS, 15,17 cannot be applied due to its low sensitivity. 22 In the present study, we performed a comprehensive flow cytometric analysis of the maturing granulocytic, monocytic, and erythroid lineages in BM aspirates of 81 RCC patients, collected prospectively by the European Working Group of MDS in Childhood (EWOG-MDS), and in BM aspirates of healthy controls, advanced MDS and (v)SAA patients.…”

Section: Introductionmentioning

confidence: 99%

Bone marrow immunophenotyping by flow cytometry in refractory cytopenia of childhood

Aalbers¹,

Heuvel‐Eibrink²,

Baumann³

et al. 2014

Haematologica

View full text Add to dashboard Cite

Refractory cytopenia of childhood is the most common type of childhood myelodysplastic syndrome. Because the majority of children with refractory cytopenia have a normal karyotype and a hypocellular bone marrow, differentiating refractory cytopenia from the immune-mediated bone marrow failure syndrome (very) severe aplastic anemia can be challenging. Flow cytometric immunophenotyping of bone marrow has been shown to be a valuable diagnostic tool in differentiating myelodysplastic syndrome from non-clonal cytopenias in adults. Here, we performed the first comprehensive flow cytometric analysis of immature myeloid, lymphoid cells and erythroid cells, and granulocytes, monocytes, and lymphoid cells in bone marrow obtained from a large prospective cohort of 81 children with refractory cytopenia. Children with refractory cyotopenia had a strongly reduced myeloid compartment, but not as severe as children with aplastic anemia. Furthermore, the number of flow cytometric abnormalities was significantly higher in children with refractory cytopenia than in healthy controls and in children with aplastic anemia, but lower than in advanced myelodysplastic syndrome. We conclude that flow cytometric immunophenotyping could be a relevant addition to histopathology in the diagnosis of refractory cytopenia of childhood. (The multi-center studies EWOG-MDS RC06 and EWOG-MDS 2006 are registered at clinicaltrials.gov identifiers 00499070 and 00662090, respectively).

show abstract

“…[12][13][14] Aberrant expression of the lymphoid antigen CD7 on myeloid blasts, for instance, correlates with poor clinical outcome. 13,15,16 Therefore, we addressed the question whether FCM analysis was instrumental in predicting response to a standardized Epo/G-CSF regimen. 17 Bone marrow samples were evaluated for chromosomal anomalies according to International System for Cytogenetic Nomenclature guidelines.…”

Section: Introductionmentioning

confidence: 99%

Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment

Westers

Alhan

Chamuleau

et al. 2010

Blood

View full text Add to dashboard Cite

Advanced pediatric myelodysplastic syndromes: Can immunophenotypic characterization of blast cells be a diagnostic and prognostic tool?

Abstract: Our data suggest that the blasts phenotypic features can constitute a diagnostic and prognostic tool also for pediatric MDS.

Cited by 28 publications

References 35 publications

Loss of B cells and their precursors is the most constant feature of GATA-2 deficiency in childhood myelodysplastic syndrome

Loss of B cells and their precursors is the most constant feature of GATA-2 deficiency in childhood myelodysplastic syndrome

Bone marrow immunophenotyping by flow cytometry in refractory cytopenia of childhood

Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment

Contact Info

Product

Resources

About